PuzzleVirtuoso12
2月前
This is remarkably well-timed — the alignment is direct and significant. Here’s the breakdown:
The NetraMark Paper (April 9, 2026)
NetraMark published a peer-reviewed article in Frontiers in Pharmacology on April 9, 2026, proposing a testable hypothesis linking psychedelics, calcium/phosphate biology, and possible spin-dependent (quantum-level) processes. The paper frames inter-individual treatment variability as structured biological heterogeneity, and outlines a translational pathway to biomarker-guided, explainable-AI trial design — directly aligned with the NetraAI platform. ?
Trump’s Executive Order (April 18, 2026 — today)
President Trump signed an executive order today to fast-track FDA review of psychedelic drugs including psilocybin and ibogaine for mental health conditions. He directed $50 million in federal funds toward the effort and ordered FDA to issue National Priority Vouchers to three psychedelics — potentially enabling approvals in just weeks. The ceremony included RFK Jr., Dr. Oz, and Joe Rogan, who Trump credited with helping push the initiative. ?
The order also directs the DEA and FDA to establish a pathway for eligible patients to access investigational psychedelic drugs, and directs the Attorney General to initiate rescheduling reviews upon successful Phase 3 trial completion. ?
How They Align
This is strong tailwind for NetraMark’s position:
1. Clinical trial demand surges — The publication supports a broader industry shift: clinical trial success in CNS disorders and psychedelic therapeutics may increasingly depend on identifying patient-level heterogeneity rather than relying on population averages ? — exactly what Trump’s order is now incentivizing with federal dollars.
2. NetraAI becomes more valuable — As psychedelic trials accelerate, sponsors will need tools to explain why some patients respond and others don’t. NetraMark’s AI subgroup identification platform is purpose-built for this.
3. Regulatory timing — The quantum-biology framework in the paper could help explain the notoriously inconsistent response rates in psychedelic trials, giving regulators a mechanistic rationale — something the FDA will likely demand as they fast-track reviews.
4. $50M federal matching fund — HHS is directed to allocate at least $50 million through ARPA-H to support state-level psychedelic drug programs ?, which creates downstream demand for the kind of biomarker-enriched trial design NetraMark offers.
Bottom line for AINMF: The paper dropped 9 days before a White House executive order that validated the entire thesis. The timing couldn’t be better for NetraMark’s positioning with sponsors, CROs, and investors in the psychedelic therapeutics space.
BlairWill
3年前
The AI Company that Will Make Money - Leveraging Large Language Models with NetraAI for Clinical Trial De-Risking: Launching NetraGPT
Joseph Geraci, PhD, CTO/CSO, Bessi Qorri, PhD, Scientific Communications Manager, & Luca Pani, MD, Chief Innovation and Regulatory Officer
NetraAI represents a distinctive, Good Clinical Practice (GCP)-authenticated machine learning architecture that offers an accessible interface for researchers to engage with consolidated multimodal datasets. This empowers sponsors to uncover explainable patient subgroups pertaining to efficacy, toxicity, and placebo response across an array of therapeutic domains, such as oncology, psychiatric disorders, neurodegenerative disorders, and rare diseases. The innovative NetraMark algorithms enable the employment of Large Language Models (LLMs), including the likes of ChatGPT, to absorb the potent hypotheses generated by the NetraAI platform from sponsor provided clinical trial patient populations, thereby enhancing the articulation of findings with increased explainability and context. NetraAI essentially functions as a data microscope, amplifying vital patient population data, and enabling new discoveries.
https://www.netramark.com/netragpt-white-paper
The true strength of the NetraAI architecture stems from its capability to discern distinct combinations of variables defining patient subpopulations, in correlation to drug or placebo response and adverse reactions—elements of key importance in clinical trials. The output of NetraAI comprises hypotheses embodied as a collection of variables and subpopulations, bolstering biostatistics, as well as supplying data to train universally applicable models. We have crafted a system whereby the output from NetraAI is fed into generative pre-trained (GPT) models using LLM APIs. Specifically, the integration of the ChatGPT API with NetraAI amplifies our capacity to generate reports that deliver clear, succinct insights to sponsors, thereby facilitating informed decision-making for their clinical trials. This novel NetraGPT module is in alignment with our mission to offer augmented intelligence algorithms capable of learning from clinical trial data, in the face of inherent challenges related to these smaller and diverse datasets.
BlairWill
3年前
NetraMark is Unleashing the Power of Artificial Intelligence to Revolutionize the Pharmaceutical Industry
The market is awash with the talk of Artificial Intelligence (AI) and Machine Learning (ML). The most recent quarter of tech earnings had many of the “big guys” (Apple, Alphabet/Google, Microsoft, Meta) talking about their AI capabilities and where it was leading them.
In fact, just yesterday Alphabet Inc.’s (NASDAQ: GOOGL) stock surged as much as 5% after it made several AI announcements at its developer conference.
Microsoft Corporation (NASDAQ: MSFT) has invested in ChatGPT, which seems to have helped its share performance this year.
And despite the dire warnings of Elon Musk, Steve Wozniak, and the “godfather of AI” Geoffrey Hinton, it seems AI is sparking a bit of an investment frenzy, at least until something else comes along to capture the market’s attention.
AI: A Complex and Diverse Field
However, AI isn’t exactly a definitive thing. Simply stating you are using AI is a little bit like saying I’m going on a holiday. You don’t know where I’m going, how I’m getting there, or what I plan to do on my holiday.
It’s one thing to use AI to generate a viral video that sounds like a collaboration between Drake and The Weeknd and another thing to do something useful (although you may argue a viral video is a useful thing).
Daily InvestorIntel updates
Your email
Even more granular, you can have an industry that is using AI to advance technology or improve efficiency but still have very different approaches or algorithms tackling a variety of unique issues. In other words, an article on AI could be way longer than anything I intend to discuss today.
Instead, I’m simply going to have a look at one example of how a company is putting its own twist on AI for the benefit of humanity and hopefully its investors.
NetraMark Holdings – A Unique Approach to AI in the Pharmaceutical Industry
That company is NetraMark Holdings Inc. (CSE: AIAI). NetraMark is a software technology company dedicated to improving the understanding of how patients, within and across diseases, relate to each other through the integration of multiple types of data via unique AI-enhancing software targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. And hopefully, that’s as complex a sentence as there is in this article.
NetraMark is addressing a market where less than 12% of the candidate medicines successfully make it through the clinical trial process and receive approval from the FDA. Given all the unsuccessful biotech companies I’ve participated in, I find that a very easy statistic to believe.
NetraMark is utilizing its proprietary AI algorithm to review where trials have failed and improve the success rate (see the complex sentence above). In other words, just because a specific trial might have failed, it doesn’t mean the drug candidate wasn’t successful, it might just be that it isn’t successful for certain people but wildly successful for others. The challenge becomes using AI to figure this out.
NetraMark’s Focus on Small Data Sets
Over 95% of drug trials have less than 1,000 people participating in them, which is a pretty small data set. Typically small data sets aren’t conducive to the use of AI.
Where NetraMark is unique is that Founder, Chief Scientific and Technology Officer, Dr. Joseph Geraci has spent over 5 years developing AI algorithms that focus on deriving statistically relevant findings in small data sets. Their product provides an intuitive interface for scientists to interact with small datasets to uncover connections related to efficacy, toxicity, and placebo response. The Company has published numerous White Papers on how their technology has identified various insights on topics ranging from pancreatic cancer to Alzheimer’s disease progression to lung cancer.
Potential for Growth
And the best part for investors is, this isn’t something that is still in development. It’s functional and running today. Last week NetraMark announced the completion of a recent client engagement to utilize outcome data collected in Phase 3 clinical trials from a specialty biopharma company. This was part of a Master Service Agreement whereby the Company earned a fixed fee for a defined Scope of Work.
NetraMark is guiding toward contracts valued at C$2 to C$3 million for the current fiscal year and C$7 to over C$9 million for next year.
Acquisitions in the AI Drug Discovery Space
Of course, that assumes the Company even makes it until next year. On Monday of this week, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a leading clinical-stage biotech company announced it has signed agreements to acquire two companies in the AI drug discovery space: Cyclica Inc. and Valence Discovery.
What makes this relevant? In February 2022, NetraMark partnered with Cyclica Inc. to accelerate drug discovery targeting neurodegenerative diseases.
Given Cyclica is a private company, it’s hard to determine what type of multiple the $40 million price Recursion paid represents. But it does confirm that the AI frenzy is heating up.
Source: S&P Capital IQ
Disclaimer: The author of this post may or may not be a shareholder of any of the companies mentioned in this column. None of the companies discussed in the above feature have paid for this content. The writer of this article/post/column/opinion is not an investment advisor, and is neither licensed to nor is making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence. To access the InvestorIntel.com disclaimer and other important legal notices, click here.
Thugmuffin
4年前
$MNNDF NUROSENE HEALTH INC. ANNOUNCES CHANGE IN MANAGEMENTPress Release | 06/10/2022
NUROSENE HEALTH INC. ANNOUNCES CHANGE IN MANAGEMENT
Canada NewsWire
TORONTO, June 10, 2022
TORONTO, June 10, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF) announces that Blake Sing has resigned from his role as Chief Financial Officer and Corporate Secretary of the Company effective today.
The Company thanks Mr. Sing for his contributions to Nurosene and wishes him the best in his future endeavours.
About Nurosene
Nurosene is a healthtech company focused on delivering innovative AI-based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly-owned subsidiary of Nurosene, is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.
Forward-Looking Statements
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of prevailing economic conditions, regulatory decisions, competitive factors in the industries in which the Company operates, changes to the Company's strategic growth plans and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
For more information, visit www.nurosene.com.
SOURCE Nurosene Health Inc.
Thugmuffin
4年前
$MNNDF NUROSENE HEALTH INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENTPress Release | 06/08/2022
NUROSENE HEALTH INC. ANNOUNCES CLOSING OF PRIVATE PLACEMENT
Canada NewsWire
TORONTO, June 8, 2022
TORONTO, June 8, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF) is pleased to announce that it has completed a closing of a non-brokered private placement in which it issued 1,487,500 units (the "Units") at a price of $0.40 per Unit for aggregate gross proceeds to Nurosene of $595,000. Each of the Units is comprised of one common share (each a "Common Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles its holder to acquire one additional Common Share at a price of $0.60 for a period of 24 months from the closing date. Nurosene intends to use the proceeds from the Units for working capital purposes.
Nurosene Health Inc. Logo (CNW Group/Nurosene Health Inc.)
Two directors of Nurosene (the "Insiders") purchased, indirectly, an aggregate of 775,000 Units for a total consideration of $310,000. The issuance of Units to the Insiders constitutes a related party transaction, but is exempt from the formal valuation and minority approval requirements of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as Nurosene' securities are not listed on any stock exchange identified in Section 5.5(b) of MI 61-101 and neither the fair market value of the Units issued to the Insiders, nor the fair market value of the entire private placement, exceeds 25% of Nurosene' market capitalization. Nurosene did not file a material change report with respect to the participation of the Insiders at least 21 days prior to the closing of the private placement as the insider participation was not determined at that time.
As a result of closing the private placement, there are 41,777,489 Common Shares of Nurosene issued and outstanding. Under applicable securities legislation, the securities issued in the private placement are subject to a four-month and a day hold period, expiring on October 9, 2022.
About Nurosene
Nurosene is an AI healthtech company focused on addressing both acute and non-acute brain-centric conditions. We have developed an ecosystem of innovative products that directly support brain-related conditions. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease. For more information, visit www.nurosene.com.
Forward-Looking Statements
Certain statements contained in this news release may constitute forward-looking information including the use of proceeds. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of prevailing economic conditions, regulatory decisions, competitive factors in the industries in which the Company operates, changes to the Company's strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
Thugmuffin
4年前
$MNNDF NUROSENE ANNOUNCES RESEARCH PARTNERSHIP IN ONCOLOGY WITH THE ONTARIO INSTITUTE FOR CANCER RESEARCHPress Release | 04/13/2022
NUROSENE ANNOUNCES RESEARCH PARTNERSHIP IN ONCOLOGY WITH THE ONTARIO INSTITUTE FOR CANCER RESEARCH
Canada NewsWire
TORONTO, April 13, 2022
Nurosene will utilize its powerful AI platform to leverage genome sequencing data in pancreatic cancer from the Ontario Institute for Cancer Research (OICR) to identify biomarkers that could help clinicians identify optimal medications for patients suffering with the disease.
TORONTO, April 13, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI-based technology solutions for mental performance and wellness announces partnership, via its wholly owned subsidiary NetraMark Corp. ("NetraMark"), with the Ontario Institute for Cancer Research (OICR), a collaborative research institute that conducts and enables high-impact translational cancer research. The effort will focus on pancreatic cancer, a global therapeutics market worth an estimated USD $2.59 billion.1
Logo (CNW Group/Nurosene Health Inc.)
The goal of the project is to identify genetic biomarkers related to pancreatic cancer. The results from this research will provide clinicians an understanding on how to best target the disease and which medication is optimal for each patient, supporting the advancement of precision medicine. Each year, more than 14 million people worldwide are diagnosed with cancer and more than 8 million people die from the disease.2 Pancreatic cancer is particularly insidious with a 5-year survival rate of just 10%.3
"Applying our technology to identify biomarkers in pancreatic cancer adds to our existing efforts in oncology. We are excited to now be working with OICR on this important project that has the potential to have a significant impact on survival rates. This data can be further utilized to discover new therapeutic products in oncology with our current partners," said Nurosene's Chief Scientific Officer, Dr. Joseph Geraci.
Nurosene's powerful technology represents a new paradigm of machine learning, moving from machines that rely on human-generated labels to causal machine learning that teaches us about disease and how to best treat individual patients. The technology allows physicians and scientists to have a deep connection with the models generated so that their expertise is optimised. Nurosene's AI platform thrives with smaller data sets and heterogeneous patient populations like cancer, neurodegenerative diseases, inflammation, psychiatric disorders, and ageing. In addition to biomarker identification, this technology will be used to accelerate new drug discovery and to prevent clinical trial failure via precise patient stratification for drug efficacy, adverse events, and placebo response.
___________________________
1
https://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market
2
https://oicr.on.ca/about/overview/
3
https://www.cancer.net/cancer-types/pancreatic-cancer/statistics
About Ontario Institute for Cancer Research (OICR)
The Ontario Institute for Cancer Research (OICR) is a collaborative research institute that conducts and enables high-impact translational cancer research. We help to accelerate the development of discoveries for patients around the world while maximizing the economic benefit of this research for the people of Ontario.
About Nurosene
Nurosene is a healthtech company focused on delivering innovative AI-based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.
For more information, visit www.nurosene.com.
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward-looking statements relating to, among others, activities of the Company's research through a partnership between the Company's wholly owned subsidiary NetraMark and the Ontario Institute for Cancer Research, potential results, uses and the impact of the research including the identification of treatments and drugs, the importance of the research, possible enhancements to our technology, growth, and other initiatives thereto.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
AskMuncher
4年前
$MNNDF NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES
Press Release | 02/10/2022
NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES
PR Newswire
TORONTO, Feb. 10, 2022
Nurosene's NetraAI Engine at the forefront to accelerate Drug Discovery with Leading Pharma Research Company
TORONTO, Feb. 10, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI based technology solutions for mental performance and wellness, is partnering, via its wholly owned subsidiary NetraMark Corp. ("NetraMark"), with Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline. This partnership agreement, signed February 7th, 2022, will leverage NetraHealthAtlas, one of Nurosene's core proprietary AI tools, to accelerate drug discovery targeting neurodegenerative diseases, a market valued at almost USD $40 Billion1. Furthermore, this partnership agreement incorporates a commercializing party milestone payment schedule and royalty payments to be payable pursuant to the terms of license agreements to be entered into between the parties as compounds are developed.
Nurosene Health Inc. (CNW Group/Nurosene Health Inc.)
Nurosene, via NetraMark, will lead in the discovery phase of the research process by identifying specific drug targets. This partnership will demonstrate the power of NetraHealthAtlas to accelerate drug target identification and to significantly reduce the costs and time associated with bringing a drug to market. Nurosene's NetraHealthAtlas is the next generation of machine intelligence designed to generate insights about patient populations and different aspects of disease. NetraHealthAtlas creates highly accurate hypotheses about invisible causal factors from patient sub-populations and then recommends ways to target a disease by exploring the necessary biochemistry involved. NetraHealthAtlas applies the learnings to treatment at a more individual level by stratifying patient data into accurate sub-models which allows for the discovery of unknown insights, unattainable with other methods and traditional AI.
"Observing the Netra Health Atlas create accurate hypotheses in less than an hour, about diseases that have taken years for pharmaceutical companies to discover, is very exciting. We have now reached a point where our AI is teaching us how to approach curing disease. The drugs that can be developed from this partnership have the potential to change the way we treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, profoundly impacting millions of patients and their families around the world," says Chief Scientific Officer of Nurosene, Dr. Joseph Geraci, PhD.
Naheed Kurji, Cyclica's President, CEO and Co-Founder, outlines his enthusiasm for the partnership, stating: "We're thrilled to be continuing to build our biotech pipeline of the future on the global stage alongside Nurosene. The NetraHealthAtlas has the ability to triangulate diseases by offering sets of targets that can work together. This unique feature fits beautifully with our poly-pharmacological approach at Cyclica, where we can attack disease from multiple approaches simultaneously."
Cyclica will use its AI-augmented drug discovery platform to discover novel drug candidates in an efficient manner for drug targets discovered by NetraHealthAtlas. The process for this partnership involves using Nurosene's technology to generate lists of protein targets from patient level genetic data of various types and will allow Cyclica's polypharmacology-enabled platform to predict molecular candidates for selected protein targets that can then be tested for disease altering properties.
"Working with a leading drug discovery company to tackle neurodegenerative diseases is an exciting opportunity for us. Through this partnership with Cyclica, we are leveraging our advanced approach to AI to develop an ecosystem that will drive the development of new molecules years faster while helping to significantly reduce clinical trial failure rates and costs by hundreds of millions of dollars," says NetraMark's President, Mark Smithyes.
About NetraMark
NetraMark, an AI and pharma-tech company, has developed proprietary next generation AI solutions for pharmaceutical and biotechnology companies. These solutions allow us to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. NetraMark is a wholly owned subsidiary of Nurosene Health Inc.
For more information, visit www.netramark.com
About Nurosene
Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.
For more information, visit www.nurosene.com.
About Cyclica
Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease. Our work spans dozens of collaborations with large pharma and biotech as well as several joint ventures. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labour at the intersection of our collective expertise. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com.
For further information about Cyclica, please contact:
Jennifer Sacco, Director of Marketing and Communications
jennifer.sacco@cyclicarx.com
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, Nurosene's research activities through its wholly owned subsidiary, NetraMark Corp. in partnership with Cyclica Inc., its potential results, uses and the impact of the research including the identification of drug candidates and acceleration of a drug IP portfolio, the importance of the research, possible enhancements to our technology and clinical trial AI offering, growth, and other initiatives related thereto.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
1 https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market#:~:text=The%20Neurodegenerative%20Disease%20market%20was,2.30%25%20over%20the%20forecast%20period.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nurosene--cyclica-partner-to-develop-novel-drugs-for-neurodegenerative-diseases-301480163.html
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
CA Market News
4月前
Renee
3年前
MyelSasha
4年前
SidewaysTrader
5年前
TommyBoyTrader9460
5年前
Screech691
5年前
SpaceManTrades
5年前
メールアドレスで登録
